LANR news

Latest 1 stories · newest Nov 18, 2026

LANR
Lantern Reports Q3 2026 Results, Closes $4M Offering

Lantern Pharma achieved mixed operational results, with R&D costs decreasing by 36% while reporting a net loss. The company announced the engagement of the first clinical site for a TNBC trial and closed an approximately $4.0 million registered direct offering.

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same LANR feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/LANR/newsSTART FREE